HOME > BUSINESS > Sun Pharma to get dengue vaccine technology from ICGEB

Sun Pharma to get dengue vaccine technology from ICGEB

iggebPharma major Sun Pharma said it tied up with research organization International Centre for Genetic Engineering and Biotechnology to develop vaccines for dengue.

The vaccine is targeted against all the four serotypes of Dengue virus that cause disease in humans and is being developed to commercialize in Indian and international markets.

A serotype is a serologically distinguishable strain of a microorganism.

Currently, half of the global population lives under dengue threat; and an estimated 390 million infections occur worldwide every year with approx. 100 million cases of clinical disease and over 25,000 deaths. All four dengue virus serotypes are now endemic in India.

Currently, there are no available antivirals, which presents a public health challenge in India and other parts of the world, including developed nations. There is no specific treatment other than supportive clinical care, which is extremely difficult in developing countries with poor resources.

“Our new collaboration with ICGEB for developing an affordable dengue vaccine is part of our programme for developing new and improved vaccines and drugs against flaviviruses that are of significant health importance to India and rest of the world,” said Kirti Ganorkar, Executive VP & Head, Global Business Development, Sun Pharma.

International Centre for Genetic Engineering and Biotechnology (ICGEB) has developed a dengue vaccine based on a tailored recombinant virus-like-particle (VLP). The vaccine contains host-receptor binding domain of envelope protein of all the four dengue virus serotypes.

According to the agreement signed, ICGEB shall disclose and make available to Sun Pharma all such existing ICGEB know-how as well as effective completion of technology transfer by ICGEB to Sun Pharma within stipulated timeframe. Sun Pharma will fund & support further development of the vaccine candidate and existing ICGEB know-how and patents.

ICGEB will grant Sun Pharma exclusive rights and licenses for development and commercialisation of this vaccine globally and it will receive pre-defined royalty & payments.

The Company has past experience in development of Hep-B and Typhoid vaccines, as well as complex vaccines, such as HPV and Malaria.

Dengue is a neglected mosquito-borne viral disease that is rapidly spreading globally. Dengue incidence has increased by more than 30-fold in the past 50 years.

The Sun Pharma – ICGEB dengue vaccine candidate is expected to provide a competitive edge over others in all three critical parameters of Safety, Efficacy & Affordability that define an ideal dengue vaccine.

ICGEB has conducted pre-clinical studies over the past seven years and developed the existing Know-How and Patents for this dengue vaccine candidate.

“The immediate priority of this partnership is to complete the Toxicology studies for further development of the program,” Sun Pharma said.

This is the second collaboration between Sun Pharma and ICGEB focusing on dengue.

The first one announced in May 2016 was related to the development of a botanical drug for treatment of Dengue. The current collaboration is focussed on developing a safe & effective vaccine for the prevention of dengue.

Initial findings of ICGEB’s dengue vaccine indicate that the candidate induces serotype specific non-cross-reactive and strongly neutralizing antibodies without disease enhancing concerns.

These features of the candidate vaccine differentiate this vaccine development programme from other vaccine programs that are developed or in development globally.

This vaccine development will focus on suitability for all target population whether previously affected or non-affected, including paediatric and adults and traveller population.

Dr Salunke, Director – International Centre for Genetic Engineering and Biotechnology (ICGEB) said, “Despite recent approval of a dengue vaccine and several candidates being at advance stage of clinical trials, the development of a safe, affordable and efficacious dengue vaccine still faces major challenges. Our pre-clinical data is very encouraging and this could be an ideal dengue vaccine candidate for all target populations.”

Sun Pharma is the world’s fifth largest specialty generic pharmaceutical company and one of India’s largest pharmaceutical company.

It provides affordable medicines in over 150 countries across the world.

Sun Pharma’s global presence is supported by 47 manufacturing facilities spread across 6 continents. The consolidated revenues for 12 months ending March 2016 are approximately U$ 4.3 billion.

It has 32 brands and 14 API manufacturing facilities across the globe.

The International Centre for Genetic Engineering and Biotechnology is an international, non-profit research organization.

The ICGEB provides a scientific and educational environment and conducts innovative research in life sciences for the benefit of developing countries. It strengthens the research capability of its Members through training and funding programmes and advisory services and promotes biotechnology internationally.

The Centre is dedicated to advanced research and training in molecular biology and biotechnology and applies the latest techniques in the fields of biomedicine, crop improvement, environmental protection/remediation, biopharmaceuticals and biopesticide production.

Follow ULTRA.news
Wipro opens Artificial Intelligence research facility in Israel University IT and outsourcing services provider Wipro said it will use students at Israel's largest university to jointly conduct research into artificial intelligence.The company inked an agreement with Tel Aviv University, Israel's largest institution of higher learning which is home ...
Glenmark Pharma gets UK OTC approval for anti-malarial medicine Glenmark Pharmaceuticals said it received approval from UK authorities for to sell its Maloff Protect anti-malarial medication without prescription.It contains atovaquone and proguanil hydrochloride, and has been available only as a prescription medicine in the UK.The Me...
Sun Pharma selects Samsung to manufacture psoriasis drug Sun Pharma said it has inked a long-term agreement with Samsung BioLogics under which the Korean company will manufacture Tildrakizumab, a potential treatment for plaque psoriasis, for the Indian company.Plaque psoriasis is an autoimmune condition which results in patches of ...
Strides Shasun gets USFDA nod for nausea drug Pharmaceutical company Strides Shasun said it received approval from the United States Food & Drug Administration to sell nausea drug Promethazine Hydrochloride in the country.The US market for Promethazine Hydrochloride tablets is approximately USD 17 Million.It will be ...
Unichem Labs says USFDA completes inspection of Goa facility Unichem Laboratories said the US FDA has completed its inspection of the company's formulations manufacturing facility in Goa.Unichem Labs' formulations plant in GoaThe facility has received an Establishment Inspection Report, the company added."This receipt indica...
Zydus Cadila gets approval for obesity drug in USA Zydus Cadila said it received the final approval from the US FDA to market obesity drug Phentermine Hydrochloride.The drug will be marketed in the form of orally disintegrating tablets in strengths of 15 mg, 30 mg, and 37.5 mg.The drug is used to treat obesity in people w...
Zydus Cadila gets nod to sell ADHD drug in USA Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals received final approval from the US Food and Drug Administration to sell generic drug Dextroamphetamine Sulfate.Dextroamphetamine is a central nervous system stimulant used in the treatment of Attention Deficit Hyp...
Zydus Cadila gets USFDA nod for Hepatitis B drug Zydus Cadila has received the final approval from the the US Food and Drug Administration to market Hepatitis B drug Entecavir.The drug has sales of $166.3 million in the US, and will be sold in 0.5 mg and 1 mg dosage.It will be produced at the group's formulations manufa...
Glenmark gets USFDA approval for generic joint-pain drug in US Glenmark Pharmaceuticals said it received final approval from the United States Food & Drug Administration for marketing a generic version of joint-pain drug Indocin of Iroko Pharmaceuticals.The drug has annual sales of approximately $6.3 million.With this, Glenmark’s ...
NIV to help Sun Pharma test Zika, Dengue and Chikungunya drugs Sun Pharma announced a tie-up with National Institute of Virology (NIV) under the Indian Council of Medical Research for testing various compounds for treating rapidly spreading viral infections -- Zika, Chikungunya and Dengue.The compounds will include those sourced from pl...
Lupin launches skin ointment in the US Pharma Major Lupin said it launched Desoximetasone cream for treating skin problems in the US market.The company had received approvals from the US Food and Drug Administration earlier.The drug is the generic equivalent of Tarot Pharma's Topicort, which had US sales of $...
Anil Ambani Group ties up with Thales for Rafale contracts Reliance Defence, the defence manufacturing arm of the Anil Ambani group, said it will form a joint venture in India with global defence manufacturer Thales to carry out some contracts related to the Rafale jet deal.The Indian company will hold 51% of the equity while the fo...
Alembic Pharma to launch generic version of AstraZeneca heart drug in USA Alembic Pharmaceuticals said it received approval from the US Food & Drug Administration for selling a generic equivalent of AstraZeneca's heart drug Atacand.Approval was granted for the sale of candesantan cilexetil in the dosage of 32 mg.Candesartan cilexetil is used ...
Glenmark Pharma buy rights to cancer drug from US firm Glenmark Pharmaceuticals said it entered into a licensing agreement with Boston-based biopharmaceutical company APC Therapeutics Inc for exclusive rights for a cancer drug.The agreement covers a small molecule based on Antigen Presenting Cell (APC) biology, the Indian compa...
Zydus Cadila gets USFDA approval for generic version of popular migraine drug Zydus Cadila said it received final approval from the US Food and Drug Administration to market migraine drug Eletriptan Hydrobromide in the US.The drug is currently marketed and manufactured by Pfizer Inc and sold in the US and Canada under the brand name Relpax.The two...
Lupin launches generic antidepressant in the US India's second biggest pharmaceutical company Lupin said it has launched the generic version of Valeant's Wellbutrin antidepressant tablet Wellbutrin XL in the US.Wellbutrin XL tablet has yearly US sales of USD 758 million or about Rs 5,000 cr.It is used for the treatment...
Aurobindo Pharma launches kidney drug in the US Aurobindo Pharma said it received final approval from the US Food & Drug Administration to manufacture generic version of kidney drug Renvela from Genzyme.Sevelamer Carbonate oral suspension, 0.8 gm and 2.4 gm is being launched immediately, the company said.The drug had ...
Lupin gets USFDA approval for pain relief drug Pharma Major Lupin said received final approval for launching a generic version of Mallinckrodt Inc.'s Roxicodone Tablets in the United States.The drug is used for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are...
Suven Life Sciences gets US, Australia patent for CNS molecule Suven Life Sciences Ltd said it got a patent from Australia and another from the US for a new molecule used for treating disorders associated with Neurodegenerative diseases.The 'new chemical entity' patent no 2014358652 from Australia is valid through 2032, while that from ...
Jet Airways inks codeshare agreement with Aeromexico Jet Airways said it inked an agreement with Aeromexico, the flag carrier airline of Mexico, to explore codeshare arrangements and shared frequent flyer programs. As part of the arrangement, both carriers will code on each other’s services between India and Mexico via common ...
Unichem Labs Ghaziabad plant inspected by USFDA Generic drug manufacturer Unichem Laboratories said its formulations manufacturing facility at Ghaziabad has successfully exited an inspection by the US Food and Drug Administration.Inside a Unichem plantIt received an Establishment Inspection Report (EIR) from the USFDA...
Zydus Cadila gets USFDA approval for generic form of colitis drug Lialda Zydus Cadila said the US Food and Drug Administration has given the final approval to market the company's Mesalamine Delayed-Release Tablets in the US market.Zydus Cadila was the first to file an Abbreviated New Drug Application (ANDA) for a generic version of Lialda.L...
Strides Shasun gets USFDA approval for ibuprofen Pharmaceuticals manufacturer Strides Shasun said it received approval from the United States Food & Drug Administration (USFDA) for ibuprofen Tablets 200 mg for over the counter sales.According to Ri data, the US market for ibuprofen Tablets USP 200 mg (OTC) is approximately...
Baba Ramdev’s Patanjali expands Ruchi Soya tie-up, eyes 20,000 cr edible oil sales Patanjali Ayurved, the consumer products company headed by yoga exponent Baba Ramdev, has scaled up its agreement with Ruchi Soya, which has been facing financial stress due to high debt levels.Ruchi Soya said the two companies have agreed to expand their initial agreement --...
Cipla redraws Iran plans with new agreement, to invest Rs 121 cr Cipla said its wholly owned subsidiary of the Company in Netherlands will set up a 75% joint venture with Ahran Tejarat Company for manufacturing and marketing of pharmaceutical products in Iran.An earlier agreement executed by the Company with the Iranian firm has been termi...